干扰素联合达沙替尼治疗慢性粒细胞白血病的疗效探讨

目的探讨达沙替尼联合干扰素-α治疗慢性粒细胞白血病的临床疗效。方法选取慢性髓细胞性白血病患者34例,根据治疗方法不同分为治疗组(n=19)和对照组(n=15)。治疗组给予达沙替尼联合干扰素-α治疗,对照组给予达沙替尼治疗,比较2组总有效率、完全缓解率、临床症状体征消失时间及不良反应。结果胸骨压痛消失时间、脾肿大肋缘下未触及时间、血常规及骨髓象恢复正常时间均减少,差异有统计学意义(P<0.05);治疗组患者治疗后完全缓解率(78.95%)明显高于对照组的完全缓解率(53.33%),差异有统计学意义(P<0.05);治疗组的总有效率(94.74%)高于对照组的总有效率(66.67%),差异有统计学意义(P<0.05);治疗组不良反应发生情况低于对照组,差异有统计学意义(P<0.05)。结论达沙替尼联合干扰素-α治疗慢性粒细胞白血病疗效确切,不良反应少,值得临床推广应用。

Objective To investigate the clinical efficacy of Dasatinib combined with interferon -it in treatment of chronic myeloid leukemia. Methods All 34 patients with chronic myeloid leukemia according to the different treatment methods were divided into two groups,19 eases in the observation group, 15 cases in the control group,the observation group treated with Dasatinib and interferon-ct treatment,control group was treated with Dasatinib therapy, the total efficient rate,completed remission rate,clinical symptoms disappeared time and Adverse reactions were compared between two groups. Results The complete remission rate was 78.95% and The efficiency rate was 94.74% in the observation group, was significantly higher than that in control group （53.33%,66.67%） with significant difference（P〈0.05）; the observation group patients with sternal tenderness disappearing time, splenomegaly subcostal untouched time,blood and bone marrow recovery time compared with the control group with significant difference（P〈0.05）; the observation group in Adverse reactions of CML was lower than the control group （P〈0.05）. Conclusion Dasatinib combined with interferon et-2 b in treatment of chronic myelogenous leukemia have good curative effect,Adverse reactions is lower and it is worthy of promotion and application.